Navigating CAR-T cells through the solid-tumour microenvironment
AJ Hou, LC Chen, YY Chen - Nature reviews Drug discovery, 2021 - nature.com
The adoptive transfer of T cells that are engineered to express chimeric antigen receptors
(CARs) has shown remarkable success in treating B cell malignancies but only limited …
(CARs) has shown remarkable success in treating B cell malignancies but only limited …
Cellular networks controlling T cell persistence in adoptive cell therapy
The antitumour activity of endogenous or adoptively transferred tumour-specific T cells is
highly dependent on their differentiation status. It is now apparent that less differentiated T …
highly dependent on their differentiation status. It is now apparent that less differentiated T …
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
CK Baumgartner, H Ebrahimi-Nik, A Iracheta-Vellve… - Nature, 2023 - nature.com
Immune checkpoint blockade is effective for some patients with cancer, but most are
refractory to current immunotherapies and new approaches are needed to overcome …
refractory to current immunotherapies and new approaches are needed to overcome …
Next-generation CAR T-cell therapies
RM Young, NW Engel, U Uslu, N Wellhausen, CH June - Cancer discovery, 2022 - AACR
CD19-and B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T
cells have enabled unprecedented responses in a subset of refractory patients with B-cell …
cells have enabled unprecedented responses in a subset of refractory patients with B-cell …
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
Adenosine is an immunosuppressive factor that limits anti-tumor immunity through the
suppression of multiple immune subsets including T cells via activation of the adenosine …
suppression of multiple immune subsets including T cells via activation of the adenosine …
Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders
SM Stanford, N Bottini - Nature Reviews Drug Discovery, 2023 - nature.com
Protein phosphatases act as key regulators of multiple important cellular processes and are
attractive therapeutic targets for various diseases. Although extensive effort has been …
attractive therapeutic targets for various diseases. Although extensive effort has been …
Counteracting CAR T cell dysfunction
In spite of high rates of complete remission following chimeric antigen receptor (CAR) T cell
therapy, the efficacy of this approach is limited by generation of dysfunctional CAR T cells in …
therapy, the efficacy of this approach is limited by generation of dysfunctional CAR T cells in …
PTP1B is an intracellular checkpoint that limits T-cell and CAR T-cell antitumor immunity
Immunotherapies aimed at alleviating the inhibitory constraints on T cells have
revolutionized cancer management. To date, these have focused on the blockade of cell …
revolutionized cancer management. To date, these have focused on the blockade of cell …
A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity
The inhibition of protein tyrosine phosphatases 1B (PTP1B) and N2 (PTPN2) has emerged
as an exciting approach for bolstering T cell anti-tumor immunity. ABBV-CLS-484 is a …
as an exciting approach for bolstering T cell anti-tumor immunity. ABBV-CLS-484 is a …
Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress
Due to the overexpression or amplification of human epidermal growth factor receptor 2
(HER2) with poor prognosis in a myriad of human tumors, recent studies have focused on …
(HER2) with poor prognosis in a myriad of human tumors, recent studies have focused on …